A relationship of borderline significance was seen in hormone receptor positive/HER2 negative subtype (HR: 0.839; 95% CI: 0.699–1.007).
← all excerpts
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials.
1
—
—